Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Tisotumab vedotin and cervical cancer, the FDA initially granted accelerated approval to tisotumab vedotin‑tftv on September 20, 2021, for adults with recurrent or metastatic cervical cancer who experienced disease progression on or after chemotherapy (1). On April 29, 2024, this approval was converted to traditional (full) approval for recurrent or metastatic cervical cancer with progression on or after chemotherapy, based on the results of the phase III innovaTV 301 trial.
In early 2024, the [EMA validated the marketing authorisation application](brain://QMGe2vnxWkWiArAahJp9aA/EuropeanMedicinesAgencyEmaApprova…